MAGE A3 antigen-specific cancer immunotherapeutic

Nir Peled; Ana B. Oton; Fed R. Hirsch; Paul Bunn

doi:10.2217/1750743X.1.1.19

MAGE A3 antigen-specific cancer immunotherapeutic

Nir Peled, Ana B. Oton, Fed R. Hirsch, Paul Bunn

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages II and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase II trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.

Original language	English
Pages (from-to)	19-25
Number of pages	7
Journal	Immunotherapy
Volume	1
Issue number	1
DOIs	https://doi.org/10.2217/1750743X.1.1.19
State	Published - 28 Dec 2009
Externally published	Yes

Keywords

MAGE
Melanoma
NSCLC
Non-small-cell lung cancer
Vaccine

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/1750743X.1.1.19

Cite this

@article{7942b5f556df47978d64eaef49a66695,

title = "MAGE A3 antigen-specific cancer immunotherapeutic",

abstract = "Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages II and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase II trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.",

keywords = "MAGE, Melanoma, NSCLC, Non-small-cell lung cancer, Vaccine",

author = "Nir Peled and Oton, \{Ana B.\} and Hirsch, \{Fed R.\} and Paul Bunn",

year = "2009",

month = dec,

day = "28",

doi = "10.2217/1750743X.1.1.19",

language = "English",

volume = "1",

pages = "19--25",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - MAGE A3 antigen-specific cancer immunotherapeutic

AU - Peled, Nir

AU - Oton, Ana B.

AU - Hirsch, Fed R.

AU - Bunn, Paul

PY - 2009/12/28

Y1 - 2009/12/28

N2 - Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages II and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase II trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.

AB - Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages II and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase II trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.

KW - MAGE

KW - Melanoma

KW - NSCLC

KW - Non-small-cell lung cancer

KW - Vaccine

UR - https://www.scopus.com/pages/publications/77953473376

U2 - 10.2217/1750743X.1.1.19

DO - 10.2217/1750743X.1.1.19

M3 - Review article

C2 - 20635969

AN - SCOPUS:77953473376

SN - 1750-743X

VL - 1

SP - 19

EP - 25

JO - Immunotherapy

JF - Immunotherapy

IS - 1

ER -

MAGE A3 antigen-specific cancer immunotherapeutic

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this